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Abstract. Background: Esophageal cancer is the ninth
most common cancer. The only potentially curative
treatment is surgical resection, which unfortunately is still
associated with major complications, the most important
being anastomotic leakage, currently with an overall rate
of up to 26% morbidity. The aim of this systematic review
was to evaluate the relationship between anastomotic
leakage and recurrence of disease. Materials and Methods:
A literature search was systematically performed. Seven out
of 312 articles dated between 2009 and 2018 fulfilled the
selection for a total of 5,433 patients. Results: The
frequency of anastomotic leakage ranged from 7.2 to
11.2%. Patients affected by anastomotic leakage had a
recurrence rate of 9-56%. Conclusion: Closer follow-up or
even more aggressive oncological therapy should be
considered for patients affected by anastomotic leakage
after surgery for carcinoma of the distal esophagus and
gastroesophageal junction. 
Esophageal cancer is reportedly the ninth most common
cancer and the sixth most common cause of cancer-related
death globally, with a 5-year survival rate of about 20%,
therefore still representing an important oncological issue (1). 
Esophageal cancer is classified as squamous cell carcinoma
or adenocarcinoma. Both occur more commonly in men.
Squamous cell carcinoma is the most common histology in
Asia, while adenocarcinoma is most common in North
America and Western European countries, according to
National Comprehensive Cancer Network Guidelines Version
1 Esophageal and Esophagofastric Junction Cancers, 2017 (2).
In the revised American Joint Committee on Cancer
(AJCC) staging system, tumors whose midpoint is in the
lower thoracic esophagus, gastro-esophageal junction (GEJ)
or within the proximal 5 cm of the stomach extending into
the GEJ or esophagus (Siewert types I and II) are classified
as adenocarcinomas of the esophagus for staging purposes.
All other cancer located more than 5 cm distal to the GEJ,
or within 5 cm of the GEJ but not extending into the GEJ or
esophagus (Siewert type III) are staged using the gastric
cancer staging system (3). 
The only potentially curative treatment is surgical
resection, which unfortunately is still associated with major
complications; for example, the frequency of anastomotic
leakage (AL), one of the most important causes of morbidity,
in the literature varies between 7.2 and 13.6% (4). 
AL affects long-term survival in patients after colorectal
cancer surgery because of increased hospital stay, higher
reoperation rates, wound infection, pneumonia and sepsis.
This can eventually result in failure or delay in referring
patients for adjuvant chemotherapy (5). The effect of
morbidity after esophageal and GEJ surgery on oncological
outcomes is not well established, with fragmentary and
discordant results (6). 
Due to the lack of consensus, the aim of this systematic
review was to evaluate the relationship between AL and
recurrence of disease, by pooling the results currently
available in the literature.
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Materials and Methods 
Search strategy. We conducted a systematic search of PubMed,
EMbase, Cochrane Library, CILEA Archive, BMJ Clinical Evidence
and Up ToDate databases with the following search terms: “Cancer”
AND “esophageal” (or “esophagus”) AND “esophagogastric
junction” AND “anastomotic leakage” (or fistula or dehiscence)
AND “recurrence” or “relapse” or “disease-free survival”). All
reference lists from the studies selected by electronic searching were
cross-checked for further identification of other relevant studies.
Unpublished reports were excluded.
Study selection. The search was limited to articles written in English
from January 1998 through April 2018. The complete article was
retrieved when the information in the title or abstract appeared to
meet the objective of this review. In addition, the reference lists of
the studies thus obtained were searched manually for any relevant
articles not found in the computerized search. We considered
prospective and retrospective studies, whether multicentered or not,
on esophagectomy performed for esophageal and GEJ cancer. The
following inclusion criteria were set: i) English language study; ii)
open or minimally invasive surgery with curative intent (with
histological confirmation of R0 status; iii) cases of GEJ
adenocarcinoma or esophageal adenocarcinoma or esophageal
squamous cell carcinoma; iv) studies mentioning recurrence rates
with or without disease-free survival (DFS). The following
exclusion criteria were set: i) Treatment for disease recurrence; ii)
case report; iii) letter; iv) review. 
Data extraction and quality assessment. Two Authors (GB, GM)
independently screened the articles by title, abstract and key words,
and then selected and analyzed the articles. Any disagreement was
resolved by discussion or with the opinion of the senior Author (PA). 
PRISMA statement guidelines for conducting and reporting
systematic reviews were followed (7). The research protocol was
registered at the International Prospective Register of Systematic
Reviews (http://www.crd.york.ac.uk/PROSPERO) with the
following registration number: CRD42018104854 (8). The
Newcastle–Ottawa Scale was the instrument used for quality
assessment; this was developed for nonrandomized studies in order
minimize bias risk in systematic review and is recommended by the
Cochrane Collaboration (9). Three broad perspectives are used to
judge a study evaluating selection of the study group, comparability,
ascertainment of either the exposure or outcome of interest for case–
control or cohort studies, respectively (10). Newcastle–Ottawa Scale
quality assessment of the included studies is presented in Table I. 
Results 
Study selection. The literature search yielded 10,824 articles;
10,512 were not considered suitable for the abstract or
integral reading, including duplicate removal; 312 titles and
abstracts were then reviewed (Figure 1). Of these, 295 were
excluded because they did not conform to our review
requirements. Finally, only 17 articles were selected for full-
text review and, of these, 10 more were excluded: One
because it reported too few cases to draw conclusions, as the
authors themselves declared (11); two more because they did
not report outcomes of interest, such as overall survival or
disease-free survival (12, 13); five because they did not report
recurrence rates in patients with occurrence of AL, although
hypothesizing a possible relationship (14-18); and two
because they did not report recurrence rates at all (19-20).
There was no disagreement regarding eligibility of full-text
articles (Cohen kappa=1). Finally, a total of seven articles
fulfilled the selection criteria and were therefore included in
this systematic review (21-27); this pool of articles were
retrospective reports. Characteristics of the included studies
are presented in Table I, which shows patient information,
and in Table II, which demonstrates outcomes of interest.
All these articles included a total of 5,433 adult patients
who underwent surgical treatment for esophageal and GEJ
cancer. The studies included were assessed for quality and
the results are presented in Table I. Outcomes of interest of
each single study are summarized in Tables II and III. 
Age at presentation. All the articles in this systematic review
reported the age of patients at presentation of the disease,
except that by Hii et al. (22). The median age ranged from
60.6 to 68 years and was not correlated with AL incidence
(Table I).
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Table I. Characteristics of the included studies (all retrospective clinical studies).
Authors, year (Ref)                           Country            Histology              Study                 Patients,                AL,       Median age,     Gender,        NOS 
                                                                                                                 period                       n                     n (%)            years              M/F           score
Lerut et al., 2009 (21)                      Belgium              S, AC             2005-2006                  138                10 (7.2)             63               111/27            8
Hii et al., 2013 (22)                         Australia              S, AC             1998-2011                  618                69 (11.2)           NR              523/95            7
Markar et al., 2015 (23)                    France                S, AC             2000-2010                 2439             208 (8.5)            60.6           2000/439          9
Kofoed et al., 2015 (24)                  Denmark              S, AC             2003-2011                 1085               93 (8.5)             63             860/225           8
Andreou et al., 2016 (25)                Germany              S, AC             2005-2012                  471                41 (8.7)             65              352/119           8
Tam et al., 2016 (26)                             US                    AC,               1997-2010         334 after PMS       95 (NR)             68              644/119           7
Belmouhand et al., 2017 (27)          Denmark           AC, GEJ           2003-2011                  348                36 (10.3)           68              297/51            9
AL: Anastomotic leakage; NL: no leakage; AC: adenocarcinoma; S: squamous cell carcinoma; GEJ: gastroesophageal junctional; NR: not reported;
NOS: Newcastle-Ottawa scale; PMS: propensity match score.
Recurrence and AL. Among the 5,433 cases, the total
number of recurrences, cases of AL and the associations
between these two factors are highlighted in Tables II and
III, article by article. Table III present a summary of the
data of interest. Three out of seven studies dealt only with
patients with recurrence (22, 23, 26); the others included
cohorts of patients with or without recurrence or AL (21,
24, 25, 27).
AL rates patients with recurrence was 9-13%. All the
included studies reported oncological outcomes of the study
cohorts, however, we focused our work on the association
between the following two variables: Recurrence and
disease-free survival, as highlighted in Table III.
Discussion
Some research studies have shown a relationship between
surgery and oncological prognosis and its possible role in
growth and metastasis of malignant tumor cells (27),
although this relationship is still not clear. In our review, we
found patients presenting with recurrence after AL following
surgery performed for esophageal or GEJ tumor. The
definition of this relationship is crucial in order to select the
population of patients susceptible to recurrence who might
benefit from more intensive follow-up. Despite the few
articles on the relation between AL and recurrence, this
relationship can be speculated. In our study, we found, as
demonstrated by others, many factors could be implied in
this relationship, including cell-mediated immunity,
cytokines, and inflammatory pathway (27), thus allowing us
to have a biological basis to the relationship sought in the
articles, one by one.
Regarding the possible pathophysiological basis of the
correlation between AL and recurrence, in a literature review,
Beecher et al. already demonstrated how surgical trauma,
inflammatory response, intraoperative tumor manipulation,
growth factors released during the procedure and tumor
growth have significant relevance in recurrence (28). 
Surgery itself can lead to suppression of cell-mediated
immunity, and diffusion of malignant cells into the
bloodstream, therefore increasing the metastatic potential,
and non-locoregional recurrence was also taken into
consideration (23, 27).
Among studies taken into account, there is no uniqueness of
results regarding the role of AL in influencing recurrence or
not. However, all the most statistically significant studies taken
into consideration by our group reported the evidence of an
impact of AL on recurrence. Lerut et al. in their work including
138 patients did not demonstrate a statistically significative link
between AL and recurrence (p=0.7077), but this result might,
partly, be due to few patients taken into account (21). In
contrast, their study reported a significant correlation between
occurrence of complications and the timing of recurrent
disease, with due regard more to the severity of the
complication, rather than AL itself. Hii et al. described the
impact of postoperative morbidity on disease-free and overall
survival after esophagectomy for 618 patients. They reported
both medical and surgical complications, sorting these into
independent categories, such as AL, in order to evaluate the
impact on median survival. However, with the occurrence of
complications, their study shown only longer duration of in-
patient stay, without a clear influence on disease-specific
survival. Therefore, they reported two main groups of patients,
those who received neoadjuvant therapy followed by surgery
and those who underwent surgery alone. The interesting aspect
of this study was how for the surgery-alone group, the
univariate analysis showed a significant association, but not the
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Figure 1. Study selection algorithm. 
multivariate one. In the group treated with neoadjuvant therapy
followed by surgery, both univariate and multivariate analyses
were negative (22). Markar et al. intended to demonstrate
exactly the impact of severe esophageal anastomotic leak upon
locoregional cancer recurrence (23). They considered severe
leak as a symptomatic leakage of intrathoracic anastomosis,
defined as Clavien-Dindo III/IV (28). In the final analysis,
2,439 patients were included, among them 1,129 patients
underwent neoadjuvant treatment. The total number of ALs
was 208, with a recurrence rate of 56.1%. On the other hand,
the recurrence rate among 2,231 patients who did not
experience AL was significantly lower at about 48.5%
(p=0.009). Indeed, the subsequent statistical study showed
greater overall recurrence [odds ratio (OR)=1.35, 95%
confidence intervaI (CI)=1.15-1.73; p=0.011], including both
locoregional (OR=1.56; 95%CI=1.05-2.24; p=0.030) and
mixed (OR=1.81, 95%CI=1.20-2.71; p=0.014), in patients
affected by AL, therefore agreeing with our hypothesis. In the
same way as us, they sought pathophysiological reasons to
explain this relationship, stressing the importance of the
proinflammatory environment, with many chemical mediators,
such as cytokines and acute-phase reactants, which may be
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Table II. Primary outcomes of each included study.
                                                                                                                                5-Year DFS (%)                                          OS, months
Authors, year (Ref)                      Follow-up duration, 
                                                                months                AL, n                    AL                          NL                           AL                                NL
Lerut et al., 2009 (21)                           (32-72)                   10                       NR                          NR                          NR                                NR
Hii et al., 2013 (2)
 Surgery alone                                    51 (2-151)                69            22% (p=0.251m)             65%                22 (p=0.516m)                       52
  Neoadjuvant                                                                                        32% (p=0.674u)              36%                41 (p=0.818u)                        41
Markar et al., 2015 (23)                            54                      208         34.9% (p=0.005)*          47.9%             35.8 (p=0.002)*                     54.8
Kofoed et al., 2015 (24)                            29                       93                        27                          39%                         NR                                NR
Andreou et al., 2016 (25)                   35 (1-101)                41            35% (p=0.037)*            58.8%             39% (p=0.001)*                    61%
Tam et al., 2016 (26)                                35.6                     95                       NR                          NR                  26.8 (9.2-99)          43.1 (IQR=18-178) 
                                                                                                                                                                                   (p=0.014)*                    (p=0.014)
Belmouhand et al., 2017 (26)            38.5 (18-69)               36                       NR                          NR                          NR                                NR
AL: Anastomotic leakage; DFS: disease-free survival; IQR: interquartile range; NL: no leakage; NR: not reported; OS: overall survival; mmultivariate
analysis; uunivariate analysis. Data are median values (range). *p-Value reported in the reference article. 
Table III. Relationship between recurrence and anastomotic leakage.
Authors, year (Ref)                                      No. of patients                           Recurrence, n (%)                       No recurrence, n (%)                 p-Value
Lerut et al., 2009 (21)                                         138                                            Total: 47                                         Total: 89                            0.7077
                                                                                                                              AL: 4 (9%)                                    AL: 6 (7%)
Hii et al., 2013 (22)                                             618                                        DFS: AL: 32*                                                                                0.674
                                                                                                                                                              NL: 36
Markar et al., 2015 (23)                                      208                                   AL (5 years): 56.1%                                    NR                                 0.009
                                                                            2331                                   NL (5 years):48.5%
Kofoed et al., 2015 (24)                                    1085                                           Total: 369                                       Total: 716                            0.004
                                                                                                                            AL: 39 (11%)                                  AL: 54 (8%)
                                                                                                                           NL: 330 (89%)                               NL: 662 (92%)
Andreou et al., 2016 (25)                                    471                                           Total: 144                                       Total: 327                            0.048
                                                                                                                            AL: 19 (13%)                                  AL: 23 (7%)
                                                                                     
Tam et al., 2016 (26)                                            334                                              AL: 38                                               NR                                 0.228
                                                                                                                                  NL: 30 
Belmouhand et al., 2017 (27)                              348                                           Total: 120                                       Total: 228                             0.34 
                                                                                                                           AL: 15 (12.5%)                              AL: 21 (9.2%)                   (univariate
                                                                                                                          NL: 107 (87.5%)                           NL: 207 (90.8%)                   analysis)
AL: Anastomotic leakage; DFS: disease-free survival; NL: non anastomotic leakage; NR: non reported. *According to AL presence, recurrence not
specified. 
responsible for tumor cell proliferation and progression to
metastasis. In conclusion, Markar et al. showed statistically
significant evidence on how AL adversely affects cancer
prognosis, thereby increasing recurrence, providing therefore
strong evidence in terms of the number of patients involved in
their large multicenter study (23). In their study, 33 patients
(23.9%) underwent induction chemotherapy or radiotherapy.
They did not specify the number of patients with AL affected
by recurrence or vice versa. Therefore, it was not possible to
speculate on its influence on recurrence rates. Using Cox
proportional-hazards regression and evaluating timing of the
recurrences, compared with patients with grade zero Clavien–
Dindo score, a statistically significantly higher recurrence rate
was recorded in patients with higher Clavien-Dindo grades.
They also proposed Clavien–Dindo classification as a
interesting tool that can enable precise documentation of
postoperative complications, based on severity. 
Kofoed et al. included 1,085 patients in their study. They
reported the impact of intrathoracic AL after curative
resection of esophageal or GEJ cancer, investigating whether
AL was associated with increased risk of recurrence. They
demonstrated a significantly increased risk of cancer
recurrence after intrathoracic AL [hazard ratio (HR)=1.63;
95%CI=1.17-2.29, p=0.004] in patients who underwent
intended curative resection for gastroesophageal cancer,
supporting our hypothesis. They explained this relationship
by attributing a modified immunological response as being
responsible for providing better conditions for growth of
circulating tumor cells (23). In their study, AL was
associated with a significantly higher risk of recurrence
(HR=1.63, 95%CI=1.17-2.29; p=0.004) and all-cause
mortality (HR=1.57, 95%CI=1.23-2.05, p<0.0001). They
attributed this poor outcome to inflammatory response,
generated by AL. Therefore, mediastinitis, infection in the
pleural cavity, and septicaemia might also facilitate the
metastatic cascade that eventually leads to disease
recurrence. They furthermore highlighted how the possible
delaying of postoperative oncology therapy could be a
critical factor implied in an increased risk of recurrence. 
Another included retrospective study, by Andreou et al.,
was aimed at investigating whether AL could predict
diminished long-term survival after resection for gastric and
esophageal cancer, also reporting the correlation between
leakage and recurrence, taken into account in our study. This
study also included gastric cancer, which could be a
potentially source of bias for our research. They included
471 patients, 47% of them affected by esophageal tumor;
12.9% suffered AL. In their statistical analysis of patients
with esophageal cancer, they confirmed the role of AL as a
risk factor of increased probability of recurrence (HR=1.74,
95%CI=1.03-2.96, p=0.037), therefore confirming our
suggestion of an association between AL and recurrence: in
their multivariate analysis for predictors of disease-free
survival, AL (p=0.037) was associated with a high risk of
recurrence (25).
Like us, they inquired about biological features, raising
the possibility that implied generalized immune suppression,
or the depression of cell-mediated immunity (especially
natural killer cells and cytotoxic T-lymphocytes) might be
invoIved in promoting spread and growth of
micrometastases. They also attributed the development of a
proinflammatory environment, which can promote cancer
cell survival and proliferation, to AL. All these factors were
also considered to be involved in increased risk of systemic
recurrence. Indeed, they considered the risk of systemic
recurrence as the most relevant, the liver being the most
common site, therefore suggesting the possible systemic
effects of circulating factors. As well another article cited
(26), they also considered delayed administration of adjuvant
systemic therapy responsible for increased risk of recurrence. 
An interesting work written by Tam et al. included 334
patients and was carried out in the USA (26). All patients
included in their study underwent minimally invasive
surgery. The study was particularly focused on the rate of
infection and the correlation this had with recurrence, taking
advantage of propensity score matching, a tool used to create
similar groups in order to reduce errors. We included this
work for the important considerations it makes regarding the
correlation between AL and outcome: There was no
statistically significant difference in recurrence rates between
propensity-matched cohorts with and those without AL
(n=38 versus n=30; p=0.228), nor in disease-free survival
(Breslow p=0.158), or median time to recurrence in those
whose disease recurred (14.14 versus 15.2 months; Wilcoxon
signed-rank test p=0.552). In the propensity-matched AL
data set, the median time to follow-up was 35.6 months; 75%
of matched patients with AL died during follow-up (n=71)
compared with 64% (n=61) of patients without. Median
overall survival was 26.8 months (interquartile range=9.2-99
months) versus 43.1 months (interquartile range=18-178
months) in the group without AL (Breslow p=0.014). After
adjusting for recurrence, R0 resection status, age at
operation, positive circumferential margin, age-adjusted
Charlson comorbidity index score, sex, body mass index,
induction therapy, and pathological stage (American Joint
Committee on Cancer, seventh edition), postoperative AL
was independently associated with a 60% increased hazard
of death during follow-up compared with patients without
AL (HR=1.60, 95%CI=1.12-2.89) (26). 
The last study, performed by Belmouhand et al., included
348 patients and evaluated recurrence following curatively-
intended surgery for GEJ adenocarcinoma. Oncological
perioperative chemotherapy was administered to 220
patients. This study was carried out in Denmark, like
another included work by Kofoed et al. (24). However, they
were located at different centers. Furthermore, Belmouhand
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et al. included only junctional adenocarcinoma, considering
a smaller number of patients (348 vs. 1,085). The
information of our interest showed how recurrence
occurred in 120 patients (34.5%), with 32 local (9.2%), and
88 distant (25.3%) recurrences, verified with biopsy.
Nevertheless, they did not find any factors associated with
site-specific recurrence. Only a trend toward local
recurrence was identified for patients who had AL
(HR=2.64, 95%CI=0.89-7.86; p=0.08) (27). It is worthy of
mention how the other Danish study (24), including a larger
cohort of patients, showed not a trend but instead a clear
link between AL and local recurrence, as mentioned in our
discussion above.
Furthermore, we did not find correlation in the selected
studies on the relationship between T-stage and adjuvant
therapy, nor between stage and adjuvant therapy. It is
interesting to note that four studies found no relationship
between AL and recurrence rate; this could be due to the
number of patients included. It is important to underline that
in the work by Tam et al. (26), once the corrective factors
for bias were applied, AL was proven to reduce long-term
survival, even not correlated with the recurrence rate.
Moreover, all the most numerically important studies show
how the data support our hypothesis. The total number of
patients who experienced AL was 5,433 among the included
studies: 3,995 experienced recurrence versus 1,438 who did
not. The pathophysiological basis which supports our
hypothesis is that esophageal surgery lead to
immunosuppression, and a cytokine storm contributes to
creating a microenvironment that favors a more rapid
recurrence than the group not exposed to this particular
complication. Different systems of AL evaluation were used
in the included studies. Lerut et al. used a modified version
of the Clavien classification, with different well-defined
grades of severity (21). In the study by Markar et al., only
clinically significant severe esophageal AL was considered
(23). Severe esophageal AL was defined as a symptomatic
(mediastinal abscess, mediastinitis or digestive content in the
chest drain) disruption of the intrathoracic anastomosis,
classified as grade III or IV according to the Clavien-Dindo
classification (29). For Kofoed et al., AL was defined
radiologically, or using an acute computed tomography scan
performed because of clinical signs of leakage (fever, chest
pain, saliva or gastrointestinal content through chest drain)
(24). Hii et al. also used the same methods of AL diagnosis
(22). For Andreou et al. AL was identified by routine
radiocontrast agent swallow examination, also including
nonclinical AL (25). Tam et al., on the other hand,
considered grade II-IV AL or conduit leak (26). Belmouhand
et al. evaluated AL with either an oral X-ray with contrast
agent, computed tomography with an oral contrast agent, or
gastroscopy. Patients with AL were categorized as requiring
an intervention (Clavien–Dindo score ≥3) (27).
Considering how AL might influence prognosis, we
believe the technique used for anastomosis is worthy of
mention. Therefore, we comment on an interesting article
written by Wong et al. (30) This study focused on how, after
discouraging results after the introduction of the circular
stapler, a single layer of continuous suture was reconsidered
over time as the best technique for achieving the best results.
Using this technique, the clinical leakage rate fell to 2%, thus
demonstrating how this hand-sewn technique was superior.
Wong et al. emphasized the technical aspect, specifying in
particular that the two parts in this hand-sewn technique
should be lightly apposed, and not approximated tightly, in
order to avoid edge strangulation. They also demonstrated
how visual satisfaction could predict outcome by defining
anastomosis as “’Simple’ when it was straightforward and
looked pleasing, ’Problematic’ when there were some suture
placement issues but it still felt secure, and ’Difficult’ when
there was a struggle to complete it and it looked a little
ragged at the end” (30). AL rates according to these
categories were 3%, 6% and 16%, respectively (30). Given
the negative impact of postoperative complications on short-
term outcomes and long-term oncological outcomes it seems
clear how those results need to be prospectively investigated. 
Other studies did not particularly focus on the relationship
we investigated here but we include them in our discussion
because they reported interesting accomplishments, which
indirectly support our hypothesis, or because they appraised
aspects about AL useful for the purpose of our research. 
First of all, we considered an article by Rasmussen et al.
which evaluated the influence of postoperative complications
on the survival. A total of 133 patients were enrolled in this
study cohort, with a mean age of 65 years. AL was proven
by water-soluble contrast swallow, CT scan (31). Patients
without complications had long-term survival of 52%. On
the other hand, among patients with one or more
complications, long-term survival was reduced to 30% (log-
rank p=0.039). The most relevant factors were AL and
sepsis/septic shock. However, Rasmussen et al. did not
report the number of patients affected by recurrence nor the
number of patients who experienced AL, considering only
the impact of AL on OS; therefore, including their results in
Table III was not possible. Adjusted Cox regression analysis
revealed that postoperative complications were associated
with an increased mortality risk with an adjusted HR of 2.02
(95%CI=1.1-3.7, p=0.025). In particular, they demonstrated
how patients with AL had a significantly higher risk
(adjusted for age, gender, tumor stage of a poor outcome),
which was demonstrated by a higher HR of 2.37,
95%CI=1.17-4.81, p=0.016. 
Rizk et al. highlighted how surgical technical
complications had a significant negative impact on overall
survival (multivariable HR=1.41, 95%CI=1.22-1.63,
p=0.008). However, Rizk et al. did not focus their research
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on AL in particular. On the other hand, in this study, medical
complications alone had no impact on overall survival,
including recurrence (15).
Conversely, Ancona et al. found no negative impact on
outcomes, neither regarding medical complications alone,
nor surgical complication alone, showing negative impact on
oncological outcome only if such complications occurred
concurrently (32). 
Another article that attempted to demonstrate the possible
relationship between AL and occurrence of recurrence was
written by Lindner et al. (33): they wanted to assess the
impact of the postoperative complications on long-term
outcome in patients with esophageal cancer. The study
included 134 patients who underwent transthoracic
esophagectomy between 2005 and 2010. The median overall
survival was sub-analyzed according to histological subtype.
For those with esophageal adenocarcinoma, if anastomotic
insufficiency occurred the median overall survival was 33.7
(range=3.3-91.9) months, and if not, 42.8 (range=2.6-95.3)
months. For those with esophageal squamocellular carcinoma,
the median overall survival was 40.04 (range=3.4-51.8)
months in those who experienced AL, and 30.0 (1.4-5.2)
months in those who did not (32). They did not take into
consideration the recurrence rates in patients with AL.
According to their results, neither anastomotic insufficiency,
nor neoadjuvant treatment influenced the incidence of
complications or long-term survival. The overall survival of
the total population was 38.1 (range=1.4-95.3) months (33). 
Another article which aimed to investigate the relationship
between postoperative complications and long-term survival
in patients with surgically resected esophageal squamous cell
carcinoma was taken into account in our review (34). It was
a single-institution study, including 502 consecutive patients.
Postoperative complications of Clavien–Dindo classification
grade greater than 2, occurred in 217 patients (43%). Among
those, 68 patients (13.5%) experienced AL, but the results of
their long-term clinical outcomes were combined with other
complication, such as surgical site infection, recurrent nerve
paralysis, cardiovascular complication. Overall,
postoperative complications did not affect long-term clinical
outcomes of these patients (log-rank p=0.28) (34).
Another interesting article that we selected analyzed
surgical complications and long-term survival after
esophagectomy in a nationwide Swedish cohort study (35).
The authors wanted to evaluate how acute surgical
complications after esophageal resection for cancer may
reduce long-term survival or not. Eligible patients comprised
those afflicted by esophageal or cardia cancer and who
underwent surgical resection in Sweden in 2001-2005,
including 615 patients in total. Among 567 included patients
who survived at least 90 days postoperatively, 130 (22.9%)
experienced a predefined surgical complication within 30
days of surgery. They showed acute complication might be
an independent predictor for poorer long-term survival.
Extrapolating the data of interest, they found 47 patients
afflicted by AL (7.6%), but they did not relate this to data
for recurrence. However, in the group affected by surgical
complication, the adjusted HR of poor prognosis was higher
compared to patients without such complications (HR=1.29,
95%CI=1.02 1.63). 
Furthermore, we also took into account a study published
by Carrot et al. (36), which used the Accordion Severity
Grading System (36) to categorize complications according to
the treatment responses and resource use. Patients undergoing
esophagectomy from 2000 to 2008 were considered, a total of
285 patients. In 156 patients (54.7%) neoadjuvant therapy was
used, and the operative mortality rate was 0.7%; 144 patients
(50.5%) experienced complications. This severity grading
system allowed documentation of complications and even
their relevant economic impact. Cox regression multivariate
analysis demonstrated an inversely proportional relationship
between overall survival and occurrence of postoperative
complications. Among those 285 patients, 11 were affected by
AL (3.9%). Using multivariate regression, AL was associated
with increased cost (multivariate B=0.149, p=0.05). However,
this study did not demonstrate that individual Accordion
grades affect survival or recurrence. The relatively small
number of patients with higher-level Accordion grades limited
the opportunity for a complete analysis (36).
Lagarde et al. looked notably only at death due to cancer
recurrence, thus not using recurrence itself, concluding that
postoperative medical and surgical complications were
associated in an independent pattern with the timing of death
due to recurrence, but not to death from recurrence itself
(11). Although this occurrence of complications had affinity
with our review, given the differences reported, we preferred
not to include the results of their work in our table. 
The last study that we have taken into consideration was
carried out by Attili et al. (38). This work considered the
significance of postoperative events in gastrointestinal
malignancies. This was a retrospective study conducted at
Kidway memorial institute of Oncology (2004-2006) which
evaluated patients who had undergone surgery with curative
intent for gastrointestinal malignancies. They assumed AL as
risk factor predictive of poor disease-free survival and 236
were evaluated. They found that the risk of relapse was 9.8
higher in patients with AL and the risk was uniform across
all types of gastrointestinal malignancies. They reported a
relapse rate of 19% in AL after esophagectomy. Among risk
factors for recurrence, AL had on OR of 9.8 (95%CI=4.2-
19.8, p=0.01). This study, as all the systematic reviews on
such a specific and poorly studied topic, suffers from some
bias; despite the wealth of studies reported in Asiatic
Literature, we were unable to find an article clearly focused
on the parameters we have taken into consideration for this
review; one of studies included in our research (25) also
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included curative gastric resection, not only esophageal or
junctional carcinoma. Hii et al. reported a total of 10 patients
with R1 resection (7.2%), which could be a potential source
of bias (22). Furthermore, all the included studies were
retrospective in nature, carrying an intrinsic risk of selection
bias, with a small cohort of patients, and were performed
over a long period of time (1998-2018), possibly including
heterogeneity linked to the changes in clinical practice,
technology, surgical and chemoradiotherapy protocols.
Among included retrospective studies, only the work carried
out by Tam et al. (26) considered propensity matching in
order to reduce bias. 
Indeed, changes in adjuvant chemotherapy practice may
have included some selection bias, with patients treated in
the most recent years showing better oncological outcomes
due to more effective protocols. Moreover, the different AL
evaluation among included studies might be a potential
source of bias.
Conclusion
According to the studies we reported in Table III, there is a
tendency to attribute recurrence to AL (23-25); in fact, three
out of seven studies confirmed this relationship, and in
terms of numbers, those studies are the most relevant we
found in literature to date. In the study cited which
demonstrated a link between leakage and recurrence, there
is conformity of opinions in considering proinflammatory
environment and adjuvant therapy delay as main factors
involved in an increased risk of occurrence of recurrence.
Given the negative impact of AL on short-term outcomes
and long-term oncological outcomes, it seems clear that
there needs to be further prospective investigation. In our
opinion, therefore, we consider that further studies are
necessary, even by putting together different case series, and
also investigating biomolecular markers involved, in order
to be finally able to highlight the importance of AL on the
recurrence of this disease. However, although the evidence
is not yet confirmed by prospective study or meta-analysis,
from our review, it would seem prudent to consider closer
follow-up or even more aggressive oncological therapy of
patients affected by AL.
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